We also believe that discovery of new therapeutic targets represents the goal of biomedical research on CRC at the moment, since majority of CRC are insensitive to EGFR inhibitor therapy, because of their positivity for mutations in the genes Kras, Braf, PI3KCA and PTEN. This evidence concerns the gene KRAS and colorectal carcinoma.